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Neighbor of BRCA1 (Nbr1) is a highly conserved multidomain scaffold protein with proposed roles in
endocytic trafficking and selective autophagy. However, the exact function of Nbr1 in these contexts has not
been studied in detail. Here we investigated the role of Nbr1 in the trafficking of receptor tyrosine kinases
(RTKs). We report that ectopic Nbr1 expression inhibits the ligand-mediated lysosomal degradation of RTKs,
and this is probably done via the inhibition of receptor internalization. Conversely, the depletion of endogenous
NBR1 enhances RTK degradation. Analyses of truncation mutations demonstrated that the C terminus of
Nbr1 is essential but not sufficient for this activity. Moreover, the C terminus of Nbr1 is essential but not
sufficient for the localization of the protein to late endosomes. We demonstrate that the C terminus of Nbr1
contains a novel membrane-interacting amphipathic -helix, which is essential for the late endocytic local-
ization of the protein but not for its effect on RTK degradation. Finally, autophagic and late endocytic
localizations of Nbr1 are independent of one another, suggesting that the roles of Nbr1 in each context might
be distinct. Our results define Nbr1 as a negative regulator of ligand-mediated RTK degradation and reveal the
interplay between its various regions for protein localization and function.
Receptor tyrosine kinases (RTKs) are a major superfamily
of membrane-spanning growth factor receptors with intrinsic
kinase activity, which regulate fundamental cellular processes
such as proliferation, migration, differentiation, and survival.
RTKs include, among others, insulin-like growth factor recep-
tor (IGFR), epidermal growth factor (EGF) receptor (EGFR),
fibroblast growth factor (FGF) receptor (FGFR), vascular en-
dothelial growth factor receptor (VEGFR), and platelet-de-
rived growth factor receptor (PDGFR) (26). Most RTKs are
activated by the binding of their cognate ligands, which induces
receptor dimerization and the autophosphorylation of specific
tyrosine residues within the kinase domain and the C-terminal
cytoplasmic tail, as well as the phosphorylation of constitutively
associated scaffold proteins such as FRS2. This results in the
recruitment and subsequent phosphorylation of other signaling
molecules, the assembly of multiprotein signaling complexes,
and the ultimate activation of downstream signal transduction
pathways. Such pathways include, among others, the RAS/
mitogen-activated protein kinase (MAPK) cascade also known
as the extracellular signal-regulated kinase (ERK) pathway,
the phosphatidylinositol-3-OH kinase (PI3K)/AKT pathway,
and the phospholipase C (PLC)/protein kinase C (PKC) path-
way (26). These signaling pathways in turn act on a variety of
transcription factors, the activities of which define the partic-
ular cellular outcome of a given stimulation.
Signaling from RTKs is tightly regulated by a variety of
extrinsic and intrinsic control mechanisms, the deregulation of
which is a major contributor to most cancers (35). In particular,
endocytic trafficking has emerged as a key regulator of RTK
signaling (30). Internalization is often triggered by ligand bind-
ing and the activation of RTKs on the cell surface. Receptor
internalization occurs through clathrin-dependent or -indepen-
dent mechanisms followed by trafficking through different ve-
sicular compartments once inside the cell (30).
Endocytic trafficking can regulate RTK signaling at least at
two levels. First, it can result in selective pathway propagation
or downregulation by compartmentalization. For example, the
removal of activated RTKs from the plasma membrane results
in the termination of those downstream signaling pathways
which require plasma membrane-associated molecules. These
include the PLC/PKC and the PI3K/AKT pathways, both of
which require phosphatidylinositol-4,5-phosphate (PI45P2) as
a substrate, which is absent in endosomes (8). In contrast,
ERK1/2 signaling is not limited to plasma membrane. In fact,
many studies suggested that full ERK1/2 activation depends on
the endocytosis of RTKs (10, 11, 14, 34). This has been attrib-
uted to the ERK1/2 propagating scaffolding complex P14-MP1,
which is localized specifically to late endosomes (19, 32, 33).
Another example of specific endosomal signal propagation has
been shown for AKT. The adaptor protein-containing pleck-
strin homology (PH) domain, the PTB domain, and leucine
zipper motif 1 (APPL1) can bind specifically to AKT on early
endosomes and enhance its activity (25). APPL1 also binds to
the AKT substrate glycogen synthase kinase 3 (GSK-3) and
increases its phosphorylation by AKT without affecting the
phosphorylation of another AKT substrate, tuberous sclerosis
complex protein 2 (TSC2), thereby providing pathway selec-
tivity (25).
Second, it is well established that endocytosis can act to
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downregulate RTK signaling by trafficking receptors to lyso-
somes for degradation. En route, signaling receptors are re-
moved from the limiting membrane of endosomes and en-
closed within intraluminal vesicles of multivesicular bodies
(MVBs), rendering them unable to interact with signaling mol-
ecules and susceptible to degradation by lysosomal hydrolyses
(22, 30). MVB formation begins in early endosomes and con-
tinues in late endosomes before mature MVBs are finally fused
with lysosomes (22). MVB sorting of RTKs depends on ubiq-
uitination by specific ubiquitin ligases such as CBL, followed by
the concerted action of the endosomal sorting complex re-
quired for transport (ESCRT) proteins, which direct ubiquiti-
nated cargos to the intraluminal vesicles of MVBs (22). The
importance of RTK regulation by MVB sorting and lysosomal
degradation is manifested by the fact that a variety of cancer-
associated genetic and epigenetic alterations specifically target
this pathway (18). Once internalized, however, the lysosomal
degradation route is not the only available itinerary for RTKs.
Internalized receptors can undergo recycling back to the
plasma membrane for reusage, and the balance between recy-
cling and lysosomal targeting can be a crucial determinant of
the signaling outcome (27, 28).
Nbr1 is a ubiquitously expressed multidomain scaffold pro-
tein of 988 amino acids with 90% conservation between
mouse and human (4, 37). It contains an N-terminal phox/
Bem1p (PB1) domain, a ZZ-type zinc finger (ZZ), a coiled-
coiled (CC) region, and a C-terminal ubiquitin association
(UBA) domain capable of binding to both K48- and K63-type
polyubiquitin chains (9, 36). The PB1 domain of NBR1 can
bind to the open catalytic domain of the giant muscle kinase
titin and regulate its downstream signaling in muscle cells (12).
In addition, the PB1 domain can heterodimerize with the PB1
domain of P62/sequestosome-1 (SQSTM1) (12), another scaf-
fold protein of similar architecture with proposed roles in
endosomal trafficking (7) and selective autophagy (2, 21). A
role in selective autophagy has also been proposed for NBR1,
as it was shown to associate with the mammalian homologue of
Atg8, an essential autophagosomal protein also known as mi-
crotubule-associated protein 1 light chain 3 (LC3) (9, 36). A
main LC3-interacting region (LIR) as well as a secondary
LC3-interacting region (LIR2) were identified in NBR1 (9),
and it was proposed previously that similarly to P62, NBR1 can
act as a specific adaptor for ubiquitinated cargos destined for
degradation by autophagosomes (9, 36). Recently, an in vivo
role for NBR1 in the regulation of bone mass and density has
been revealed by its genetic truncation in mice (38).
We recently reported that NBR1 associates with Spred2, a
negative regulator of ERK1/2 signaling downstream of RTKs
(15). We showed that Spred2 activity is dependent on its in-
teraction with NBR1 and that Spred2 downregulates ERK1/2
signaling downstream of FGFR by targeting the receptor to the
lysosomal degradation pathway (15). These results led us to
propose NBR1 as a novel regulator of RTK trafficking, but it
remained unclear whether the protein had any effect on RTK
trafficking on its own. Here we investigated the role of NBR1
in the context of RTK trafficking in more detail. We show that
ectopic Nbr1 expression inhibits the ligand-mediated lysoso-
mal degradation of endogenous RTKs. Live-cell imaging re-
vealed that this effect is probably due to the inhibition of
receptor internalization from the cell surface. In contrast,
small interfering RNA (siRNA) depletion of endogenous
NBR1 enhances receptor degradation. The C terminus of Nbr1
is essential but not sufficient for this function. Similarly, the C
terminus of Nbr1 is essential but not sufficient for the late
endocytic localization of the protein. We also show that in
addition to the UBA domain, the C terminus of Nbr1 contains
a membrane-interacting amphipathic -helix, which is neces-
sary for the late endocytic localization of the protein but not
for its effect and RTK degradation. Finally, we demonstrate
that the late endocytic and autophagic localizations of Nbr1
are independent, suggesting that the function of Nbr1 in each
context might be distinct. Our results establish Nbr1 as a novel
negative regulator of RTK trafficking and reveal the relation-
ship between its different regions for protein localization and
function.
MATERIALS AND METHODS
Plasmid constructs. A schematic representation of Nbr1 constructs described
in the study can be found in Fig. 1. N-terminally Myc- and green fluorescent
protein (GFP)-tagged full-length mouse Nbr1 constructs as well as an N-termi-
nally glutathione S-transferase (GST)-tagged C-terminal-only Nbr1 mutation
(P856-Y988) construct were described previously (15). All N- and C-terminal
truncation mutation constructs were made by Gateway cloning (Invitrogen)
according to the manufacturer’s instructions and as described previously (31).
Briefly, forward and reverse primers with in-frame gateway 5 overhangs corre-
sponding to the beginning and end of a target sequence were used in a PCR to
generate Gateway-compatible coding fragments. These fragments were then
recombined into the Gateway pDONR201 entry vector (Invitrogen) using the BP
clonase enzyme (Invitrogen). Myc-tagged constructs were generated by recom-
bining entry vectors into a Myc-pRK5 gateway destination vector described
previously (31) using the LR clonase enzyme (Invitrogen). GFP-tagged con-
structs were similarly generated by using the pcDNA DEST53 destination vector
(Invitrogen). The Y750A point mutation was generated by site-directed mu-
tagenesis using overlapping forward and reverses primers harboring the specific
mutation in the middle. Finally, the Nbr1 juxta-UBA (JUBA) deletion mutation
was generated from a full-length coding construct using primers with AgeI
restriction digestion site 5 overhangs. These forward and reverse primers were
targeted to just after and just before the JUBA coding sequence, respectively,
and were used in a PCR to amplify the whole construct minus the JUBA coding
sequence. The linear product was then circularized by AgeI digestion (NEB) and
FIG. 1. Schematic representation of Nbr1 mutations used in this
study. The arrow is in an N- to C-terminal direction. The indicated
amino acids are the first or last included residues in the constructs.
Nbr1 regions are represented linearly (the JUBA label applies to the
cyan portion).
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self-ligation using T4 ligase (Invitrogen). The C-terminally GFP-tagged EGFR
construct was described previously (3, 23).
Reagents and antibodies. Mouse monoclonal anti-NBR1 antibodies were pur-
chased from Abcam and Abnova (clone 6B11). Mouse monoclonal antibody
against LAMP2 (clone H4B4) was also obtained from Abcam. Mouse monoclo-
nal anti-Myc tag antibody (clone 9E10) was obtained from Roche. Rabbit mono-
clonal anti-Myc tag (clone 71D10) antibody was obtained from Cell Signaling
Technology. Anti-EGFR, GST, EEA1, cleaved procyclic acidic repetitive protein
(PARP), and cleaved CASP-9 rabbit polyclonal antibodies were also obtained
from Cell Signaling Technology. Rabbit polyclonal anti-FGFR2 (Bek), ERK1,
and mouse monoclonal anti-pERK1/2 (clone E4) antibodies were obtained from
Santa Cruz Biotechnology Inc. Mouse monoclonal anti--tubulin (clone DM 1A)
was obtained from Sigma. All fluorescently labeled (Alexa Fluor 488, Alexa
Fluor 594, and Texas Red) secondary antibodies were obtained from Invitrogen.
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG secondary
antibodies were obtained from Amersham Biosciences Inc. IRDye infrared anti-
mouse and anti-rabbit IgG secondary antibodies were obtained from Li-COR
Biosciences.
EGF was purchased from Sigma. z-VAD-FMK and bafilomycin-A1 (BafA)
were also obtained from Sigma. Nontargeting control and NBR1 siRNAs were
purchased from Santa Cruz Biotechnology Inc. The custom-made JUBA peptide
was obtained from Alta Bioscience. The GST-tagged PH domain of PLC-1
(PIP2 Grip) was purchased from Echelon Inc. Membrane lipid strips, phosphati-
dylinositol-phosphate (PIP) arrays, and all phospholipids apart from phosphati-
dylcholine were also purchased from Echelon Inc. Phosphatidylcholine was pur-
chased from Avanti Polar Lipids Inc.
Cell culture, transfection, stimulation, lysis, and Western blotting. Cell cul-
ture and transfections were performed as described previously (15). Briefly,
cells—human embryonic kidney (HEK) 293T and 293A LC3-GFP cells as well as
African green monkey simian virus 40 (SV40)-transformed kidney (COS7)
cells—were grown at 37°C in 5% CO2 in Dulbecco’s modified Eagle medium
(Invitrogen) supplemented with 10% fetal bovine serum (Labtech International).
DNA transfections were performed by using Genejuice transfection reagent
(Novagen) according to the manufacturer’s instructions, and the cells were an-
alyzed at 24 h posttransfection. Lipofectamine RNAiMAX (Invitrogen) was used
for siRNA transfections according to the manufacturer’s instructions for forward
or reverse transfections, and the cells were analyzed after 24, 48, or 72 h, with the
transfection being renewed every 24 h. For EGF and FGF2 stimulations, 293T
cells were serum starved for 6 h, and ligand (plus 10 g/ml heparin in the case
of FGF2) was added to the cells at the indicated concentrations. Lysis was
performed by the addition of 2 SDS sample buffer directly to the cells (50
l/cm2 of cells), followed by rigorous vortexing and heating to 95°C for 10 min.
Lysates were run on 4 to 12% NuPAGE Bis-Tris SDS gels (Invitrogen), and
Western blotting was performed by using Immobilon PVDF-FL (Millipore)
membranes. Membranes were dried and incubated with primary antibodies over-
night at 4°C, followed by washing and incubation with secondary antibodies for
1 h at room temperature. After additional washes, blots were visualized by
Enhanced Chemiluminescence Plus reagent (GE Healthcare) or an Odyssey
infrared imaging system (Li-COR).
Live-cell imaging, immunostaining, and confocal microscopy. Live-cell imag-
ing with a Nikon A1R/TIRF microscope system (Nikon UK) was used to analyze
receptor endocytosis and degradation. Cells transfected with GFP-tagged
EGFR, with or without the cotransfection of Myc-Nbr1, were imaged by time-
lapse epifluorescence microscopy employing a 60 objective and an Andor iXon
885 electron multiplier charge-coupled-device (EM-CCD) camera. Cells were
imaged following stimulation with EGF, and EGFR-GFP fluorescence was an-
alyzed to quantify endocytosis (number of intracellular endosomes positive for
EGFR at each time point) and degradation (total cellular intensity at each time
point). Five cells per group were analyzed, and nonstimulated cells were analyzed
as a photobleaching control. Immunostaining and confocal microscopy were
performed essentially as described previously (15). Briefly, cells grown on glass
coverslips were fixed, permeabilized, blocked, and subjected to primary and
fluorescently labeled secondary antibodies for 1 h per antibody with three washes
in between before being mounted onto Mowiol. Coverslips were subsequently
analyzed by laser scanning confocal microscopy using a Leica TCS SP2 confocal
microscope system. All images were taken sequentially and as a single section at
200 Hz using the 63 objective lens. Final images were generated from the
averages of eight consecutive scans. All presented images are representative of
the majority of cells investigated.
Liposome preparation and circular dichroism. Liposomes were prepared as
described previously (20). Briefly, phosphatidylcholine and the PIP of interest
were mixed in a glass vial at 95:5 molar ratio. The lipid mixture was dried under
an N2 gas stream, redissolved in 1:1 CHCl3-CH3OH, and dried again under an
N2 stream followed by vacuum centrifugation for 1 h to remove residual chlo-
roform. The lipids were subsequently resuspended in ultrapure H2O and sub-
jected to multiple rounds of freezing at 80°C and thawing in a 45°C sonicating
water bath until the mixture became optically clear. Circular dichroism (CD) was
performed as described previously (6). Briefly, spectra were acquired with a
Jasco J715 spectropolarimeter using 0.5-mm cuvettes (Starna/Optiglass) with
peptide concentrations of 1 mg/ml and liposome concentrations of 2 mg/ml
where applicable. Spectra were recorded from 300 nm to 180 nm with a band-
width of 2 nm, a data pitch of 0.2 nm, a scan speed of 100 nm/min, and a response
time of 0.5. Four consecutively recorded spectra were averaged for each sample,
and the relevant buffer baseline spectra were subtracted from each sample
spectrum.
RESULTS
Nbr1 inhibits lysosomal degradation of RTKs. We previ-
ously reported that NBR1 is a specific late endosomal protein
and that the regulation of FGFR trafficking and signaling by
Spred2 depends on its interaction with NBR1 (15). These
results suggested a novel role for NBR1 as a regulator of
receptor trafficking, but it remained unclear whether the pro-
tein had any direct effect on RTK trafficking on its own. We
therefore set out to investigate the trafficking role of NBR1 in
more detail, focusing on its effect on EGFR and FGFR traf-
ficking. We observed that ectopic Nbr1 expression inhibited
the ligand-mediated degradation of endogenous EGFR (Fig.
2A and C). Similarly, the ligand-mediated degradation of en-
dogenous FGFR2 was inhibited by ectopic Nbr1 expression
(Fig. 2B and C). As a result, downstream ERK1/2 signaling was
enhanced in response to both EGF and FGF2 (Fig. 2A and B).
In neither case did Nbr1 have any effect on basal receptor
levels as judged by immunoblotting (Fig. 2C). Moreover, the
effect of ectopic Nbr1 expression on EGFR (Fig. 2D and F) or
FGFR2 (Fig. 2E and F) was minimal in cells pretreated with
the lysosomal inhibitor bafilomycin-A1 (BafA), supporting the
notion that the observed difference in receptor levels is due to
the inhibition of lysosomal degradation (Fig. 2F). These results
demonstrate that Nbr1 acts to abrogate ligand-mediated RTK
degradation.
We next investigated the effect of the depletion of endoge-
nous NBR1 on the degradation of EGFR and FGFR2. In
contrast to ectopic Nbr1 expression, the depletion of endoge-
nous NBR1 in 293T cells by siRNA enhanced EGFR degra-
dation (Fig. 3A and C). Similar results were obtained with
HeLa cells, which express considerably higher endogenous
EGFR levels (Fig. 3B and C). The reduction in receptor levels
could be seen even in the absence of ligand treatment, sug-
gesting that depleting endogenous NBR1 must be sufficient to
force receptors toward the degradative endocytic route (Fig.
3C). However, a similar effect could not be detected for
FGFR2 (data not shown). Since the prolonged knockdown of
NBR1 results in cell death (15), it is very likely that the NBR1
depletion in these experiments was not complete. Thus, a pos-
sible explanation for this variation could be that FGFR2 and
EGFR simply have different sensitivity thresholds toward a
partial NBR1 depletion.
Nbr1 inhibits ligand-mediated receptor internalization
from the cell surface. In order to generate a real-time analysis
of RTK trafficking and degradation in live cells, we made use
of the well-documented GFP-tagged EGFR construct (3, 23).
We imaged the loss of EGFR from the plasma membrane and
its appearance in cytosolic endosomes, followed by subsequent
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degradation, live in HeLa cells. Following stimulation, EGFR-
GFP clearly redistributed to cytosolic punctae (Fig. 4A). How-
ever, the expression of Nbr1 decreased the endocytic traffick-
ing of activated EGFR (Fig. 4A). Quantification of the number
of EGFR-positive spots at each time point following stimula-
tion revealed that endocytosis was significantly delayed in cells
expressing Nbr1 (Fig. 4B). These results suggest that a likely
mechanism by which Nbr1 inhibits RTK degradation is via
trapping the receptor on the cell surface. Furthermore, quan-
tification of whole-cell fluorescence demonstrated that the
degradation of EGFR following EGF stimulation was signifi-
cantly attenuated in cells expressing ectopic Nbr1 (Fig. 4C).
Thus, the results of these imaging-based assays concur with
data from the above-described biochemical studies (Fig. 2C).
The C terminus of Nbr1 is essential but not sufficient for its
function and localization. We next examined the contribution
of different regions of Nbr1 to its inhibition of RTK degrada-
tion. Our previous study implicated the C terminus of NBR1 as
being important for its function, as it was sufficient to mediate
an association with SPRED2 (15). Therefore, we first com-
pared the effect of full-length Nbr1 to that of a C-terminally
deleted mutation lacking the last 133 amino acids on ligand-
mediated RTK degradation. Unlike full-length Nbr1, the C-
terminally deleted mutation did not inhibit EGFR degradation
after EGF treatment (Fig. 5A and C), and similar results were
obtained for FGFR2 (Fig. 5B and C). Accordingly, the en-
hancement of downstream ERK1/2 signaling was also lost
when the C terminus of Nbr1 was deleted (Fig. 5A and B).
Next, we compared full-length Nbr1 with a C-terminal-only
mutation (P856-Y988), which contains just the last 133 amino
acids. We observed that similarly to the prolonged depletion of
NBR1 by siRNA (15), the expression of the C-terminal-only
FIG. 2. Nbr1 abrogates ligand-mediated lysosomal degradation of RTKs and enhances downstream signaling. All error bars represent standard
errors of the means (SEM). P values were calculated by a one-tailed paired t test (n 	 3). (A) Overexpression of Nbr1 inhibits ligand-mediated
EGFR degradation and enhances downstream ERK1/2 signaling. HEK293T cells transfected with Myc-Nbr1 or GFP as a control were serum
starved and stimulated for the indicated time points with 50 ng/ml EGF. Cells were lysed and analyzed by Western blotting. (B) Overexpression
of Nbr1 inhibits ligand-mediated FGFR2 degradation and enhances downstream ERK1/2 signaling. HEK293T cells transfected with Myc-Nbr1 or
GFP as a control were serum starved and stimulated for the indicated time points with 20 ng/ml FGF2 plus 10 g/ml heparin. Cells were lysed
and analyzed by Western blotting. (C) Densitometry analysis of RTK degradation in the presence or absence of Myc-Nbr1 from panels A and B.
(D) Nbr1 inhibition of ligand-mediated EGFR degradation is BafA sensitive. HEK293T cells transfected with Myc-Nbr1 or GFP as a control were
starved and stimulated for the indicated times with 50 ng/ml EGF. Thirty minutes prior to stimulation, the specified cells were pretreated with 200
nM BafA. Cells were lysed and analyzed by Western blotting. (E) Nbr1 inhibition of ligand-mediated FGFR2 degradation is BafA sensitive. HEK293T
cells transfected with Myc-Nbr1 or GFP as a control were starved and stimulated for the indicated times with 20 ng/ml FGF2 plus 10g/ml heparin. Thirty
minutes prior to stimulation, the specified cells were pretreated with 200 nM BafA. Cells were lysed and analyzed by Western blotting. (F) Densitometry
analysis of the effect of BafA treatment on Myc-Nbr1-mediated inhibition of RTK degradation from panels D and E. TUB, -tubulin.
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mutation induced cell death by apoptosis (Fig. 5D), but this
could be inhibited by a general caspase inhibitor, z-VAD-FMK
(Fig. 5E). Unlike full-length Nbr1, the C-terminal-only Nbr1
mutation was not capable of inhibiting ligand-mediated EGFR
(Fig. 5F and H) or FGFR2 (Fig. 5G and H) degradation in
cells treated with z-VAD-FMK. The enhancement of down-
stream ERK1/2 signaling was also lost (Fig. 5F and G). To-
gether, these results suggest that the C terminus of Nbr1 is
essential but not sufficient for the inhibition of RTK degrada-
tion.
As Nbr1 specifically localizes to the limiting membrane of
late endosomes (15), we asked whether this localization might
be important for the effect on RTK trafficking. Using confocal
microscopy, we investigated the late endocytic localization of
different Nbr1 mutations. As expected, full-length Nbr1 exhib-
ited a strong colocalization with the late endocytic marker
LAMP2 (Fig. 6A). The deletion of the two N-terminal do-
mains, the PB1 and ZZ domains, did not have an effect on
protein localization (Fig. 6B). However, the loss of the C-
terminal 133 amino acids (P856-Y988), which results in the loss
of protein function (Fig. 5A, B, and C), had a dramatic impact
on protein localization (Fig. 6C). This deletion resulted in the
loss of colocalization with LAMP2, and the protein exhibited a
diffuse cytosolic localization instead of a vesicular localization
(Fig. 6C). Similarly, when a C-terminal-only (P856-Y988) Nbr1
mutation was investigated, it showed no colocalization with
LAMP2 (Fig. 6D). However, this mutation was still localized to
the limiting membrane of some intracellular vesicular struc-
tures (Fig. 6D). These vesicular structures were larger than full
length (Fig. 6D) and stained positive for the early endosomal
marker EEA1 (data not shown), which is suggestive of a po-
tential defect in vesicle maturation/fission. These results indi-
cate that the C terminus of Nbr1 is essential but not sufficient
for its correct localization.
The C terminus of Nbr1 is constituted of UBA and JUBA.
Having established the importance of the Nbr1 C terminus
(P856-Y988) for protein localization and function, we sought
to study this region in more detail. The C terminus of Nbr1
contains a well-conserved UBA domain (9, 36). However, a
detailed study of the C terminus also revealed another region
of high conservation that was located 10 amino acids N termi-
nal to the UBA domain (Fig. 7A). Due to its proximity to the
UBA domain, we called this region juxta-UBA (JUBA). JUBA
is only 22 amino acids long and does not seem to be conserved
in P62 (Fig. 7A). Secondary-structure prediction by JPRED-3
(5) suggests that it predominantly has an -helical fold. Pro-
jection along the helical axis of the predicted -helix of JUBA
showed a highly amphipathic conformation, with charged or
polar amino acids arranged on one side of the helix and hy-
drophobic amino acids on the other (Fig. 7A). Amphipathic
-helices are found in many proteins that peripherally associ-
ate with membrane bilayers. Examples include the epsin, am-
phiphysin, endophilin, Arf, and Arl proteins (16). These heli-
ces are characterized by being unfolded until they come into
contact with a target lipid membrane. This induces -helical
folding, and the hydrophobic side gets inserted into the bilayer,
while the polar/charged side remains outside and makes ionic
contacts with the negatively charged headgroups of membrane
lipids such as phosphatidylinositol-phosphates (PIPs) (16).
To find out whether JUBA is in fact one such -helix, we
used circular dichroism (CD) spectroscopy. CD spectroscopy is
a powerful method to determine the secondary structure of
peptides, as each secondary structure exhibits unique spectrum
signatures: unfolded peptides give spectra with a single mini-
FIG. 3. Depletion of endogenous NBR1 enhances EGFR degradation. All error bars represent SEM. P values were calculated by a one-tailed
paired t test (n 	 5). (A) 293T cells were transfected with NBR1 or nonsilencing control siRNAs for 48 h, with the transfection being renewed
after 24 h. Cells were serum starved and stimulated for the indicated times with 50 ng/ml EGF before being lysed and analyzed by Western blotting.
(B) HeLa cells were transfected with NBR1 or nonsilencing control siRNAs for 48 h. Cells were starved and stimulated for the indicated times
with 50 ng/ml EGF before being lysed and analyzed by Western blotting. (C) Densitometry analysis of EGFR levels in control or NBR1-depleted
cells from panels A and B. Note that NBR1 depletion results in a reduction of EGFR levels even prior to stimulation.
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mum at around 200 nm, whereas -helical peptides give a
maximum at around 192 nm and two minima at around 208 nm
and 222 nm (6). When we subjected a peptide corresponding to
the predicted -helix of JUBA (L907-S924) to CD spectros-
copy, it gave an unfolded signature spectrum (Fig. 7B). The
addition of phosphatidylcholine liposomes did not affect the
folding (Fig. 7B). However, when liposomes additionally con-
taining various PIPs were added to the peptide solution, they
all induced an -helical fold, as judged by the disappearance of
the 200-nm minimum as well as the appearance of the
192-nm maximum and 208- and 222-nm minima (Fig.
7B). Finally, as a positive control the addition of trifluoroetha-
nol (TFE), an -helix-inducing agent (6), also resulted in the
induction of an -helical fold (Fig. 7B). These results show that
JUBA folds into an -helix in the presence of PIP-containing
membranes. Since every tested PIP could similarly induce an
FIG. 4. Nbr1 traps EGFR on the cell surface and inhibits its degradation. All error bars represent SEM. P values were calculated by a nonpaired
t test (n 	 5 cells under each condition) (*, P 
 0.05; **, P 
 0.01; ***, P 
 0.001). (A) HeLa cells were transfected with EGFR-GFP, with or
without Myc-Nbr1, and subjected to live-cell imaging by epifluorescence microscopy for 30 min following the addition of EGF (50 ng/ml). A
nonstimulated control was also included (bottom). Scale bars, 10 m. (B) Quantification of the number of EGFR-GFP-internalizing spots per area.
The overexpression of Myc-Nbr1 induces a delay of 8 min in EGFR internalization. (C) Normalized total EGFR-GFP fluorescence from whole-cell
areas. The overexpression of Myc-Nbr1 abrogates the degradation of EGFR.
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-helical fold (Fig. 7B), the results also suggest that JUBA on
its own does not display specificity toward a particular PIP.
Having shown that JUBA forms a membrane-interacting
-helix, we next tested whether the C terminus of Nbr1 exhibits
a lipid binding capacity in vitro. We used membrane strips
dotted with different physiologically relevant membrane lipids
in a technique commonly known as fat blotting. In this method,
the membrane is blotted with a GST-tagged protein of interest,
and bound proteins are subsequently detected by blotting with
a GST antibody. While GST on its own did not associate with
any of the lipids, the GST-tagged C terminus of Nbr1 (P856-
Y988) could bind to all present PIPs as well as phosphatidic
acid (PA) (Fig. 7C). As a positive control we used the pleck-
strin homology domain of PLC-1 that specifically binds
PI45P2 (13), which gave the expected result (Fig. 7C). Similarly
to PIPs, PA has a bivalent phosphate group, suggesting that
JUBA might be interacting with bivalent phosphates of the
lipid headgroups. To further confirm that the C terminus of
Nbr1 does not display specificity toward a particular PIP, we
performed fat blots using membranes dotted with increasing
concentrations of each of seven PIPs. No significant preference
was detected between different PIPs, while the pleckstrin ho-
mology domain of PLC-1 bound only PI45P2 (Fig. 7C). As
before, GST on its own did not show any lipid binding (Fig.
7C). The results confirm that at least in vitro, the C terminus of
Nbr1 binds PIPs with broad specificity.
As we reported previously, Nbr1 associates with the limiting
membrane of late endosomes (15). To determine whether the
vesicular membrane association of Nbr1 in vivo depends on
JUBA, we compared the localization of full-length Nbr1 and
the C-terminal-only Nbr1 (P856-Y988) mutation with that of a
JUBA-deleted mutation. Full-length Nbr1 was specifically lo-
FIG. 5. The C terminus of Nbr1 is essential but not sufficient for its function. All error bars represent SEM. P values were calculated by a
one-tailed paired t test (n	 3). (A and B) A C-terminally deleted mutation of Nbr1 lacking the last 133 amino acids does not inhibit ligand-induced
RTK degradation. HEK293T cells were transfected with Myc-Nbr1, Myc-Nbr1Cterm, or GFP as a control. Cells were serum starved and
stimulated with 50 ng/ml EGF (A) or 20 ng/ml FGF2 plus 10 g/ml heparin (B) for the indicated times before being lysed and analyzed by Western
blotting. (C) Densitometry analysis of RTK degradation by Myc-Nbr1 and Myc-Nbr1Cterm from panels A and B. (D) Expression of a
C-terminal-only Nbr1 mutation containing the last 133 amino acids (P856-Y988) induces cell death by apoptosis. HEK293T cells were transfected
for the indicated times with Myc-Nbr1Cterm only or GFP as a control. Cells were lysed and analyzed by Western blotting for the apoptotic markers
cleaved PARP and cleaved CASP-9. (E) Apoptosis induced by a C-terminal-only Nbr1 mutation can be inhibited by a general caspase inhibitor.
HEK293T cells transfected with Myc-Nbr1Cterm only or GFP as a control were treated with increasing concentrations of z-VAD-FMK. Cells were
lysed and analyzed by Western blotting for the apoptotic marker cleaved PARP. (F and G) The C-terminal-only Nbr1 mutation (P856-Y988) does
not inhibit ligand-induced RTK degradation. HEK293T cells were transfected with Myc-tagged full-length Nbr1 (Myc-Nbr1), Myc-Nbr1Cterm
only, or GFP as a control. A total of 50 M z-VAD-FMK was added to all cells in order to block cell loss by apoptosis. Cells were serum starved
and stimulated with 50 ng/ml EGF (F) or 20 ng/ml FGF2 plus 10 g/ml heparin (G) for the indicated times before being lysed and analyzed by
Western blotting. (H) Densitometry analysis of RTK degradation by Myc-Nbr1 and Myc-Nbr1Cterm only from panels F and G.
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calized to the limiting membrane of vesicular structures in vivo
(Fig. 7D). Similarly, the C-terminal-only mutation (P856-
Y988) exhibited localization to the vesicular limiting mem-
branes, although as mentioned above, the vesicles were rela-
tively enlarged compared to that of full-length Nbr1 (Fig. 7D).
However, a JUBA-deleted Nbr1 showed no localization to
vesicular limiting membranes and instead exhibited an aggre-
gate-like localization (Fig. 7D). These results reveal that JUBA
is essential for the Nbr1 association with vesicular limiting
membranes in vivo.
FIG. 6. The C terminus of Nbr1 is essential but not sufficient for its correct localization. Scale bars, 10 m. (A) Full-length Nbr1 colocalizes
with the late endocytic marker LAMP2. COS7 cells transfected with GFP-Nbr1 were fixed, immunostained for LAMP2, and analyzed by confocal
microscopy. (B) PB1-ZZ-deleted Nbr1 colocalizes with the late endocytic marker LAMP2. COS7 cells transfected with GFP-Nbr1PB1-ZZ were
fixed, immunostained for LAMP2, and analyzed by confocal microscopy. (C) C-terminally deleted Nbr1 lacking the last 133 amino acids does not
colocalize with the late endocytic marker LAMP2. COS7 cells transfected with GFP-Nbr1Cterm were fixed, immunostained for LAMP2, and
analyzed by confocal microscopy. (D)The C-terminal-only Nbr1 mutation (P856-Y988) does not colocalize with the late endocytic marker LAMP2.
COS7 cells transfected with GFP-Nbr1Cterm only were fixed, immunostained for LAMP2, and analyzed by confocal microscopy.
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Having established that the C terminus of Nbr1 consists of
UBA and JUBA and that JUBA is an amphipathic membrane-
interacting -helix that targets Nbr1 to vesicular limiting mem-
branes, we next sought to determine the contribution of each
region to the late endosomal localization of Nbr1. The deletion
of either UBA or JUBA resulted in the loss of Nbr1 late
endosomal localization, suggesting that both domains are cru-
cial for the correct localization of the protein (Fig. 7E). Inter-
estingly, the effect of the loss of both regions together (Fig. 6C)
is more dramatic than that of each region individually (Fig.
7E), suggesting that the two regions cooperate to localize
Nbr1.
UBA but not JUBA is necessary for Nbr1 function. Having
established the role of JUBA in Nbr1 localization, we next
sought to assess its importance in the Nbr1-mediated inhibition
of RTK degradation. While the deletion of the C-terminal
UBA domain abrogated the effect of Nbr1 on the degradation
of EGFR (Fig. 8A and C) and FGFR2 (Fig. 8B and C), the
deletion of JUBA did not have any functional impact on the
degradation of either receptor (Fig. 8A, B, and C). Thus, while
both the UBA and JUBA regions are important for the late
endocytic localization of Nbr1 (Fig. 7E), only UBA seems to be
important for the Nbr1-mediated inhibition of RTK degrada-
tion.
Late endocytic localization of Nbr1 is LIR independent.
Nbr1 contains two LIRs, which can bind to LC3 and target
Nbr1 to autophagosomes (9). As the C-terminal-only (P856-
Y988) Nbr1 mutation that lacks both LIRs (Fig. 1) cannot
correctly localize to late endosomes (Fig. 6D), we asked
whether the interaction with autophagosomes via LIRs is im-
portant for the late endosomal localization of Nbr1 since au-
tophagosomes commonly fuse with endosomes on their route
toward lysosomal degradation (29). The main Nbr1 LIR is
located close to the C terminus of the protein (V739-E779) and
contains a pivotal tyrosine (Y750), the mutation of which re-
sults in the loss of LC3 interactions (9). The second LIR
(LIR2) is located further N terminally (A543-P634) and can
compensate for the loss of the main LIR (9). When we tested
FIG. 7. The C terminus of Nbr1 contains UBA and JUBA, both of which are essential for its correct localization. Scale bars, 10 m. (A, left)
Cross-species multiple alignment of the C-terminal 93 amino acids of NBR1 reveals JUBA, a novel conserved stretch of amino acids next to the
UBA domain, which is not present in P62. (Right) Projection along the helical axis of the predicted -helix of JUBA (L907-S924) suggests that
it would be amphipathic, with polar (light green) and charged (dark green) amino acids on one side and hydrophobic amino acids (yellow) on the
other. (B) The JUBA peptide exhibits unfolded CD spectrum signatures in water or in the presence of PC and -helical spectrum signatures in
the presence of PIPs or the -helix-inducing agent TFE. CD spectra of the JUBA peptide in water (W) and water plus phosphatidylcholine (PC)
liposomes, plus phosphatidylinositol-3-phosphate (PIP3)-containing liposomes, plus phosphatidylinositol-4,5-phosphate (PI45P2)-containing lipo-
somes, plus phosphatidylinositol-3,4,5-phosphate(PI345P3)-containing liposomes, or plus 20% TFE. (C) The C terminus of Nbr1 binds to PIPs.
(Top) The C terminus of Nbr1 associates with PIPs and PA. Membranes prespotted with 15 different biologically relevant lipids were incubated
with the GST-tagged C terminus of Nbr1 (GST-Nbr1Cterm only), GST alone as a negative control, or the GST-tagged pleckstrin homology (PH)
domain of PLC-1 (GST–PLC-1–PH) as a positive control. Membranes were analyzed by blotting with an anti-GST antibody. (Bottom) The C
terminus of Nbr1 does not show specificity to any PIP. Membranes prespotted with increasing amounts of various PIPs were incubated with
GST-Nbr1Cterm only, GST, or GST–PLC-1–PH as described above and blotted with an anti-GST antibody. (TG, triglyceride; DAG, diacyl-
glycerol; PA, phosphatidic acid; PS, phosphatidylserine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; PG, phosphatidylglycerol; CL,
cardiolipin; PI, phosphatidylinositol; Ch, cholesterol; SM, sphingomyelin; SGC, 3-sulfogalactosylceramide). (D) Deletion of JUBA abrogates
membrane associations in vivo. COS7 cells transfected with GFP-Nbr1, GFP-Nbr1Cterm only, or GFP-Nbr1JUBA were fixed and analyzed by
confocal microscopy. (E) Both JUBA and UBA are necessary for late endocytic localization of Nbr1. (Top) Deletion of the UBA domain abrogates
Nbr1 colocalization with LAMP2. COS7 cells transfected with GFP-Nbr1UBA were fixed, immunostained for LAMP2, and analyzed by confocal
microscopy. (Bottom) Deletion of JUBA also abrogates Nbr1 colocalization with LAMP2. COS7 cells transfected with GFP-Nbr1JUBA were
fixed, immunostained for LAMP2, and analyzed by confocal microscopy.
FIG. 8. UBA is necessary but JUBA is dispensable for Nbr1 function. All error bars represent SEM. P values were calculated by a one-tailed
paired t test (n 	 4). (A) Deletion of UBA but not JUBA abrogates Nbr1-mediated inhibition of EGFR degradation. HEK293T cells were
transfected with Myc-Nbr1, Myc-Nbr1UBA, Myc-Nbr1JUBA, or GFP as a control. Cells were serum starved and stimulated with 50 ng/ml EGF
for the indicated times before being lysed and analyzed by Western blotting. (B) Deletion of UBA but not JUBA abrogates Nbr1-mediated
inhibition of FGFR2 degradation. HEK293T cells were transfected with Myc-Nbr1, Myc-Nbr1UBA, Myc-Nbr1JUBA, or GFP as a control. Cells
were serum starved and stimulated with 20 ng/ml FGF2 plus 10 g/ml heparin for the indicated times before being lysed and analyzed by Western
blotting. (C) Densitometry analysis of RTK degradation by Myc-Nbr1, Myc-Nbr1UBA, and Myc-Nbr1JUBA from panels A and B.
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an N-terminal truncation mutation of Nbr1 expressing residues
C terminal to G694, it could still colocalize with the late en-
docytic marker LAMP2 (Fig. 9A). As this mutation lacks LIR2
(Fig. 1), this result suggests that the loss of LIR2 alone does
not have an effect on Nbr1 localization. However, like full-
length Nbr1 (Fig. 10A), this mutation could still associate with
autophagosomes (Fig. 10B). Therefore, we further mutated
the pivotal tyrosine in the main LIR (Y750 to A) to assess
whether the complete loss of LC3 binding affects the late
endocytic localization of Nbr1. The association with autopha-
gosomes was lost with this additional mutation (Fig. 10C), but
colocalization with the late endocytic marker LAMP2 was not
affected (Fig. 9B). These results reveal that the late endocytic
localization of Nbr1 is independent of LC3 binding and auto-
phagosomal association. Interestingly, we also observed that
the C terminus of Nbr1 (P856-Y988), which is crucial for the
late endocytic localization of the protein (Fig. 6C), is not
needed for autophagosomal localization (Fig. 10D). There-
fore, we conclude that the late endocytic and autophagic lo-
calizations of Nbr1 are independent of one another: the auto-
phagic localization of Nbr1 requires the LIR but not the C
terminus, while the late endocytic localization of Nbr1 requires
the C terminus but not the LIRs.
DISCUSSION
The evidence presented in this study establishes Nbr1 as an
inhibitor of ligand-mediated RTK degradation (Fig. 2 and 3).
Live-cell imaging analysis suggests that the likely mechanism
by which Nbr1 inhibits receptor degradation is via inhibiting
receptor internalization from the cell surface (Fig. 4). The
C-terminal 133 amino acids of Nbr1 are essential for its inhi-
bition of RTK degradation (Fig. 5A, B, and C). We previously
reported that the same region of Nbr1 also binds to Spred2 and
that this binding is essential for the Spred2-mediated down-
regulation of ERK1/2 signaling by targeting the activated re-
ceptors to the lysosomal degradation pathway (15). As Nbr1
inhibits receptor degradation and consequently leads to an
enhancement of downstream ERK1/2 signaling (Fig. 2A and
B), it is possible that Spred2 binding to the critical C terminus
of Nbr1 could be interfering with Nbr1 activity. Alternatively,
Spred2 binding could be altering Nbr1 function from an inhib-
itor to an enhancer of RTK degradation. This is supported by
the fact that while NBR1 does not have a negative impact on
ERK1/2 signaling on its own, its coexpression with Spred2
results in a synergistic inhibition of ERK1/2 (15), which is
suggestive of a cooperative rather than a simply antagonistic
mechanism of functional interaction. Our results also reveal
that further regions of functional significance other than the C
terminus must exist within Nbr1, as a C-terminal-only mutation
on its own is not sufficient to inhibit RTK degradation (Fig. 5F,
G, and H).
The molecular interactions involved in the Nbr1-mediated
inhibition of RTK internalization and degradation are not de-
fined at the moment. A number of known binding partners of
Nbr1, such as P62 (12), P14, transmembrane emp24-like traf-
ficking protein 10 (Tmp21), and ubiquitin carboxyl-terminal
hydrolase 8 (USP8/UBPY) (36), have roles in vesicular traf-
ficking. USP8 is in particular very interesting in this regard, as
its loss results in the inhibition of EGFR degradation (1, 24).
USP8 deubiquitinates EGFR, and this is essential for ESCRT-
dependent MVB sorting and the subsequent degradation of
FIG. 9. Late endocytic localization of Nbr1 is independent of LIR. Scale bars, 10 m. (A) A truncated Nbr1 mutation lacking LIR2
(Nbr1G694) colocalizes with LAMP2. COS7 cells transfected with GFP-Nbr1G694 were fixed, immunostained for LAMP2, and analyzed by
confocal microscopy. (B) This truncated mutation with an additional point mutation in the main LIR (Nbr1G694Y750A) can still colocalize with
LAMP2. COS7 cells transfected with GFP-Nbr1G694Y750A were fixed, immunostained for LAMP2, and analyzed by confocal microscopy.
5682 MARDAKHEH ET AL. MOL. CELL. BIOL.
FIG. 10. Colocalization of Nbr1 with accumulated autophagosomes depends on LIR but not the C terminus. Scale bars, 10 m. (A) Full-length
Nbr1 can colocalize with autophagosomes. 293A cells stably expressing GFP-tagged LC3 were transfected with Myc-Nbr1. Cells were treated with
200 nM BafA for 4 h to accumulate autophagosomes before being fixed, immunostained for Myc, and analyzed by confocal microscopy. (B) The
Nbr1G694 mutation lacking LIR2 can colocalize with autophagosomes. 293A cells stably expressing GFP-tagged LC3 were transfected with
Myc-Nbr1G694. Cells were treated with 200 nM BafA for 4 h to accumulate autophagosomes before being fixed, immunostained for Myc, and
analyzed by confocal microscopy. (C) The Nbr1G694Y750A mutation, which lacks the LC3 binding capacity, cannot colocalize with autopha-
gosomes. 293A cells stably expressing GFP-tagged LC3 were transfected with Myc-Nbr1G694Y750A. Cells were treated with 200 nM BafA for
4 h to accumulate autophagosomes before being fixed, immunostained for Myc, and analyzed by confocal microscopy. (D) The C-terminally
deleted Nbr1 mutation lacking the last 133 amino acids (P856-Y988) can still colocalize with autophagosomes. 293A cells stably expressing
GFP-tagged LC3 were transfected with Myc-Nbr1Cterm. Cells were treated with 200 nM BafA for 4 h to accumulate autophagosomes before
being fixed, immunostained for Myc, and analyzed by confocal microscopy.
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the receptor (1, 24). In addition, USP8 has a role in the reg-
ulation of ESCRT ubiquitin recognition machinery itself by
deubiquitinating a number of its components (17). The fact
that the phenotype of ectopic Nbr1 expression mimics that of
the USP8 loss could be suggestive of a functional relationship.
It remains to be determined whether a functional epistasis
exists between the two proteins and, if so, how their interaction
regulates endocytosis and receptor degradation.
We previously demonstrated that Nbr1 is a specific late
endosomal protein (15). Here we reveal that the C terminus of
Nbr1 is essential but not sufficient for its late endosomal lo-
calization (Fig. 6C and D). We also show that unlike its C
terminus, the two LIR regions of Nbr1 are dispensable for late
endocytic localization (Fig. 9). On the other hand, the auto-
phagosomal localization of Nbr1 is dependent solely on the
presence of LIRs and not the C terminus (Fig. 10). The fact
that the late endocytic and autophagic localizations of Nbr1
are independent of each other indicates that the function of
the protein in each context might be independent of one an-
other as well. This is not surprising, as the association of Nbr1
with LC3 seems to result primarily in its removal from the
cytoplasm and degradation via the autophagosomal pathway
(9). In line with the above-described hypothesis, the inhibition
of autophagy by the siRNA-mediated depletion of its key com-
ponents did not affect the inhibition of RTK degradation by
Nbr1 (F. K. Mardakheh and J. K. Heath, unpublished obser-
vations).
As mentioned above, the C terminus of Nbr1 contains a
UBA domain, which can bind to polyubiquitin chains (9, 36).
Here we show that the C terminus also contains a well-con-
served membrane-interacting amphipathic -helix, which we
name JUBA. JUBA is crucial for the Nbr1 association with
vesicular limiting membranes (Fig. 7D), and both UBA and
JUBA are essential for the late endocytic localization of the
protein (Fig. 7E). It was proposed previously that amphipathic
-helices might act as curvature sensors, being thermodynam-
ically capable of inserting themselves into membranes with the
right degree of curvature (16). In this light, JUBA could be
providing further specificity with regard to Nbr1 localization by
acting as a specific curvature sensor. Interestingly, despite nu-
merous similarities at the level of domain architecture between
Nbr1 and P62, JUBA seems to be a unique feature of Nbr1, as
a similar region cannot be found in P62 (Fig. 7A). Thus, it is
likely that the mechanisms by which these two proteins localize
to late endosomes are different.
Finally, our results reveal that while JUBA is essential for
the late endocytic localization of Nbr1 (Fig. 7E), it is dispens-
able for its effect on RTK trafficking (Fig. 8). The late endo-
somal localization per se, therefore, does not seem to be im-
portant for the function of Nbr1 in the context of RTK
trafficking. In fact, the above-mentioned mislocalization of the
C-terminal-only Nbr1 mutation to early endosomes (data not
shown) suggests that it is probably trafficked through the en-
docytic machinery, and its late endocytic localization is there-
fore a steady-state phenomenon. The exact molecular mecha-
nism by which Nbr1 associates with the endocytic machinery
remains to be determined. The identification of novel Nbr1-
interacting partners and determination of their mode of inter-
action should help shed light on this matter.
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